Sepsis-trained macrophages promote antitumoral tissue-resident T cells

Alexis Broquet, Victor Gourain, Thomas Goronflot, Virginie Le Mabecque, Debajyoti Sinha, Mitra Ashayeripanah, Cédric Jacqueline, Pierre Martin, Marion Davieau, Lea Boutin, Cecile Poulain, Florian P. Martin, Cynthia Fourgeux, Melanie Petrier, Manon Cannevet, Thomas Leclercq, Maeva Guillonneau, Tanguy Chaumette, Thomas Laurent, Christelle HarlyEmmanuel Scotet, Laurent Legentil, Vincent Ferrières, Stephanie Corgnac, Fathia Mami-Chouaib, Jean Francois Mosnier, Nicolas Mauduit, Hamish E.G. McWilliam, Jose A. Villadangos, Pierre Antoine Gourraud, Karim Asehnoune, Jeremie Poschmann, Antoine Roquilly

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

9 Citations (Scopus)

Résumé

Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.

langue originaleAnglais
Pages (de - à)802-819
Nombre de pages18
journalNature Immunology
Volume25
Numéro de publication5
Les DOIs
étatPublié - 1 mai 2024
Modification externeOui

Contient cette citation